Gets an authorization for a treatment that combine the bamlanivimab and the etesevimab, Eli Lilly’s Anticuerpos, And It’s Destined For Adults And Thirty Nine Men As Positive As Virus And Correcting The Risk Of Getting Pregnant will not be employed in hospitalized patients or require oxygen.
At the end of November 2020, the FDA authorized the emergence of Eli Lilly’s bamlanivimab, and since several months, studies have been conducted that finalized and combined the use of this drug with the etesivimab, another antiseptic monoclonal drug called human huésped and traverses of the called pico protein.
This new authorization allows the federal governor to distribute the treatment to the state and territorial health departments for administration in closed installations.
“The action of Hoy, which proposes another treatment against covid-19, reflects the FDA’s first compromise to work with patronizers to expand the possible treatment options that medical attendees can use to help them combat it. of the FDA’s Evaluation and Investigation Center.
“The data that responds to this emergency authorization are summed up in the emerging evidence that points to the clinical utility of the neutralizing anticoagulants for the treatment of covid-19 in patient patients. As part of our Coronavirus Treatment Acceleration Program, the FDA uses all of our resources to make available treatments such as these anticorrosive monoclonal drugs continued to be studied for safety and efficiency, ”he said.
According to the agency’s communication, its emergency use authorization follows the dates that bamlanivimab and etesevimab administered together reduce the risk of hospitalizations and deaths by covid-19 by 70%, but no more patients are admitted .
The pharmaceutical promotion is this authorization, which is added to the bamlanivimab in November and which says Eli Lilly has helped reduce hospitalizations.
“In Lilly hemos dedicated our time, resources and experience to discover and develop therapies to treat covid-19”, said Daniel Skovronsky, scientific director of Eli Lilly, in a communication. “The bamlanivimab alone is an emergency use authorization and has given many people a temporary treatment option that can prevent hospitalizations and emotional states from becoming an additional therapeutic option with a clinical benefit.
As of 2021 Eli Lilly has 250,000 doses of the best treatment and hopes to have a production of up to a million doses for a year.
“With the risk that surge resistance means that various viruses appear, bamlanivimab and etesevimab together may allow the efficacy against a more extensive range of SARS-CoV-2 variants of natural origin and that these new species are extinct by todo el mundo “, says Skovronsky.
